These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 38916409)
1. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges. Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409 [TBL] [Abstract][Full Text] [Related]
2. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nogueiras R; Nauck MA; Tschöp MH Nat Metab; 2023 Jun; 5(6):933-944. PubMed ID: 37308724 [TBL] [Abstract][Full Text] [Related]
3. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Fisman EZ; Tenenbaum A Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089 [TBL] [Abstract][Full Text] [Related]
4. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
5. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097 [TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide. Nauck MA; Mirna AEA; Quast DR Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380 [TBL] [Abstract][Full Text] [Related]
7. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555 [TBL] [Abstract][Full Text] [Related]
8. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Nauck MA; D'Alessio DA Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763 [TBL] [Abstract][Full Text] [Related]
9. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis. Stefanou MI; Theodorou A; Malhotra K; Aguiar de Sousa D; Katan M; Palaiodimou L; Katsanos AH; Koutroulou I; Lambadiari V; Lemmens R; Giannopoulos S; Alexandrov AV; Siasos G; Tsivgoulis G Eur Stroke J; 2024 Sep; 9(3):530-539. PubMed ID: 38400569 [TBL] [Abstract][Full Text] [Related]
10. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Frías JP Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356 [TBL] [Abstract][Full Text] [Related]
11. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism. Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834 [TBL] [Abstract][Full Text] [Related]
12. [A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists]. Scheen A Rev Med Liege; 2024 Sep; 79(9):605-612. PubMed ID: 39262368 [TBL] [Abstract][Full Text] [Related]